Theratechnologies Inc. is a specialty pharmaceutical company. The Company is engaged in the discovery and development of therapeutic peptide products, with focus on growth-hormone releasing factor (GRF) peptides. The Company's product, EGRIFTA (tesamorelin for injection), is the therapy for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. As of November 30, 2011, the Company was marketed in the United States by EMD Serono, Inc. (EMD Serono). On January 10, 2011, EMD Serono launched EGRIFTA.
|Headquarters||2310 boul Alfred-Nobel|
MONTREAL, QC, Canada H4S2B4
|Independent Chairman of the Board||Paul Pommier|
|Interim President, Interim Chief Executive Officer, Chief Financial Officer, Senior Vice President, Director||Luc Tanguay|
|Vice President - Finance||Marie-Noel Colussi|
|Vice President - Legal Affairs, Corporate Secretary||Jocelyn Lafond|
|Vice President - Scientific Affairs and Alliances||Christian Marsolais|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||61.0M||Book Value||$0.37|
|Annual Dividend Rate||$0.00||Price/Sales (TTM)||1.3|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||--|
|Pay Date||1/1/01||Operating Margin||-43.40%|
*GAAP = prior to non-GAAP analyst adjusted earnings.